Aktis Oncology, Inc. (AKTS)
Aktis Oncology develops radiopharmaceutical cancer treatments that deliver radioactive material directly to tumors. It last closed at $16.15 on Nov 20, down 1.52% on the day. The next earnings report for AKTS is expected around Mon, Mar 29, 2027, after the close. Over its last 4 reports the stock moved an average of 6.4% the session after earnings. Over the last 12 months AKTS insiders bought $114.3M of stock on the open market and sold $3.2M, according to SEC Form 4 filings.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on AKTS
Technical AnalysisPrices may be delayed
The stock sits between its 20 and 50 day averages. It is 28% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the 20 day average at $16.10, and the nearest resistance the Pivot at $16.29.
| RSI (14) | 45.92 | Middle of its range | Neutral |
| MACD | -0.35 | Above its signal line | Bullish |
| Stochastic | 55.9 | Middle of its range | Neutral |
| ADX (14) | 19.4 | No clear trend | |
| Williams %R | -49.4 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 22.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +2.1% | Change over 10 sessions | Bullish |
| ATR (14) | $0.98 | Typical daily range, 6.0% of price |
| RSI (14) | 38.82 | Weak, oversold below 30 | Neutral |
| MACD | -1.49 | Below its signal line | Bearish |
| Stochastic | 16.3 | Near the bottom of its range | Oversold |
| ADX (14) | 19.5 | No clear trend | |
| Williams %R | -84.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -87.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −30.7% | Change over 10 sessions | Bearish |
| ATR (14) | $2.93 | Typical daily range, 18.1% of price |
What happened before
See how AKTS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options FlowPrices may be delayed
90DNo whale options trades in AKTS in the last 90 days.
AKTS Institutional Ownership
Full report →- ▲84 buying vs 41 selling
- ▲Shares held by funds +7.8%
- ▲Funds holding +11
- ▲Superinvestors: 3 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 125 | 114 | +9.6% |
| In funds' top 10 | 5 | 5 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 30 / 54 | 51 / 27 | +7.7% |
| Reduced / sold out | 23 / 18 | 18 / 6 | +70.8% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AKTS Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23 | Akos CzibereChief Medical Officer | Sale plan | 12,500 | $20.69 | $259K |
| Jul 20 | Ken HerrmannDirector | Sale | 4,856 | $24.56 | $119K |
| Jul 17 | Ken HerrmannDirector | Sale | 3,065 | $25.21 | $77K |
| Jul 8 | Akos CzibereChief Medical Officer | Sale | 50,000 | $27.77 | $1.4M |
| Jul 8 | Shulamit Ron-BiggerCOO | Sale | 50,000 | $27.75 | $1.4M |
| Jan 12 | Ansbert Gadicke10% owner | Buy | 1,112,777 | $18.00 | $20.0M |
From SEC Form 4 filings by AKTS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AKTS is in one of them and how their past AKTS trades turned out.
AKTS News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AKTS in an article yet. Here's the latest on the wider market.
About Aktis Oncology
Aktis Oncology is a company based in Boston that develops radiopharmaceuticals, which are cancer treatments that carry radioactive material directly to tumors. Its main focus is a platform built on small engineered proteins that bind to targets on cancer cells. Its lead candidate targets Nectin-4, a protein found on several solid tumor types, and is being tested in clinical trials for urothelial cancer and other tumors. The company works with isotope suppliers and contract manufacturers to supply these treatments to cancer patients and their doctors.
- Headquarters
- Boston, MA




